News & Updates

Children and adolescents with Tourette syndrome (TS) may benefit from ecopipam, a first-in-class selective dopamine-1 (D1) receptor antagonist, as it reduced the number of tics and level of daily interference in a post hoc analysis of the phase IIb D1AMOND trial.

Short-term supplementation with a selective essential amino acid (EAA)-containing product significantly improved liver-related outcomes among adolescent girls with polycystic ovarian syndrome (PCOS) in a recent study.